Drug Trial Radar · NCT03401385
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
890
Planned (sponsor's estimate)
Start
Jan 31, 2018
Primary completion
Jan 1, 2028
Study completion Jan 1, 2028
Sponsor
- Lead sponsor
- Daiichi Sankyo Co., Ltd.Daiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo; AstraZeneca
- First posted
- Jan 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is the first time the drug has been used in humans. There will be two parts and a sub-study. The primary purpose of the parts are: * Dose Escalation: To investigate the safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended dose for expansion (RDE) of DS-1062a * Dose Expansion: To investigate the safety and tolerability of DS-1062a in additional solid tumors This study is expected to last approximately 6 years from the time the first participant is enrolled to the time the last subject is off the study. Study sites are located in both the United States and Japan. The number of treatment cycles is not fixed in this study. Participants who continue to benefit from the study treatment may continue, unless: * they withdraw * their disease gets worse * they experience unacceptable side effects. The primary purpose of the sub-study is to compare the effectiveness of steroid versus non-steroid mouthwash as prophylaxis against oral mucositis/stomatitis in participants receiving DS-1062a. The sub-study is a randomized study that will include approximately 76 participants enrolling into the Dose Expansion part.
Conditions
- Hormone Receptor Positive Breast Cancer
- Triple Negative Breast Cancer
- Non-small Cell Lung Cancer
Interventions
Datopotamab Deruxtecan (Dato-DXd)Drug
A total anti-TROP2 antibody and MAAA-1181a
Steroid Containing MouthwashDrug
A mouthwash containing a steroid ingredient administered in sub-study
Non-Steroid Containing MouthwashOther
A mouthwash containing a non-steroid ingredient administered in sub-study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose-limiting toxicitiesTime frame: Within 8 cycles (each cycle is 21 days)
- Number of participants with adverse events (AEs)Time frame: When all participants have either discontinued the study or the last participant enrolled in the study has completed at least 6 months of follow up (approximately 4 years)
- Number of participants with Grade >/= 2 oral mucositis/stomatitis in Sub-StudyTime frame: At 8 weeks
Locations
18 sites in 2 countries. Site status is shown where the registry gives one.
University of California, Los Angeles
Los Angeles, California
Johns Hopkins Sibley Memorial Hospital
Washington D.C., District of Columbia
Winship Cancer Institute of Emory University
Atlanta, Georgia
Johns Hopkins University
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Tisch Cancer Institute, Icahn School of Medicine
New York, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
Sarah Cannon Research Institute
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
Next Oncology
San Antonio, Texas
START Oncology
San Antonio, Texas
Virginia Cancer Specialists
Fairfax, Virginia
National Cancer Center Hospital
Chūōku, Japan
National Cancer Center Hospital East
Kashiwa, Japan
Aichi Cancer Center
Nagoya, Aichi-ken, Japan
The Cancer Institute Hospital of Japanese Foundation For Cancer Research
Koto-Ku, Tokyo, Japan
Showa Medical University Hospital
Shinagawa-Ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.